EANO Issues Consensus Guidelines on Diagnosing and Managing Radiation Necrosis

The Diagnostic Blind Spot in Post-Radiotherapy Care

Standard neuroimaging routinely fails to distinguish between active tumor progression and necrotic tissue damage. To cut through this diagnostic fog, a panel of 20 international experts developed new guidance through a rigorous three-round Delphi process. The panel achieved at least 80% agreement across 53 out of 57 evaluated statements.

Pinpointing Perfusion MRI and PET as Advanced Modalities

To accurately differentiate radiation necrosis from recurring tumors, the panel identified perfusion MRI and amino acid PET as the most suitable imaging modalities. Histopathology remains the clinical gold standard for a definitive diagnosis. Yet, identifying viable tumor cells in previously irradiated gliomas is exceptionally difficult.

That difficulty stems from overlapping cytological features shared between reactive glial cells and residual tumor tissue. When lesions are surgically accessible, the consensus notes that surgery remains an effective option for providing rapid symptom relief alongside a definitive tissue diagnosis.

Corticosteroids, Bevacizumab, and Thermal Therapy

Managing symptomatic radiation necrosis currently lacks high-level randomized clinical trial evidence. This void prompted the EANO group to formulate expert recommendations based on available data. Clinicians may initially attempt management with corticosteroids for patients experiencing acute symptoms.

For cases that prove refractory to standard corticosteroid treatments, the panel recommends the use of bevacizumab. Clinical evidence reviewed by the panel indicates that bevacizumab exhibits profound therapeutic efficacy in these resistant cases, even when administered at low doses.

The Push for Prospective Randomized Trials

Beyond pharmacological approaches and traditional surgery, the EANO consensus document highlights Laser Interstitial Thermal Therapy (LITT) as an emerging and viable treatment option. LITT can be considered for appropriately selected patients suffering from symptomatic radiation necrosis.

Despite these actionable recommendations, the authors emphasize the complete absence of Level 1 evidence in the field. This underscores an urgent clinical need for prospective randomized trials focused specifically on symptomatic radiation necrosis management.